Saks, Nordstrom, Ma...
Health Care: Drugs
Idenix Pharmaceuticals Inc. (IDIX: NASDAQ)
$4.07 0.01 | 0.25%
05/21/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 69.66M | 6.95M | 10.22M | 12.62M |
| Cost of Sales | 2.65M | 2.32M | 2.76M | -2.98M |
| Gross Operating Profit | 67.01M | 4.63M | 7.46M | 15.59M |
| Selling, General, and Administrative Expenses | 24.16M | 16.69M | 23.44M | 21.47M |
| Research & Development | 70.18M | 41.34M | 44.51M | 41.87M |
| Operating Income before D & A (EBITDA) | -27.34M | -53.41M | -60.49M | -47.74M |
| Depreciation & Amortization | 3.10M | 4.20M | 4.58M | 5.19M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income - Net | 2.89M | 1.37M | 1.13M | 1.19M |
| Special Income / Charges | -8.04M | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -35.59M | -56.24M | -66.17M | -53.25M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -35.59M | -56.24M | -66.17M | -53.25M |
| Income Taxes | -89.00K | -61.00K | -40.00K | -27.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -32.40M | -51.98M | -61.56M | -53.22M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -32.40M | -51.98M | -61.56M | -53.22M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -32.40M | -51.98M | -61.56M | -53.22M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-24.36M | -51.98M | -59.32M | -51.71M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -32.40M | -51.98M | -61.56M | -53.22M |
| Basic EPS from Continuing Ops. | -0.27 | -0.57 | -0.87 | -0.87 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.27 | -0.57 | -0.87 | -0.87 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.27 | -0.57 | -0.87 | -0.87 |
| Basic Normalized Net Income/Share | -0.20 | -0.57 | -0.84 | -0.85 |
| EPS fr Continuing Ops. | -0.27 | -0.57 | -0.87 | -0.87 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.27 | -0.57 | -0.87 | -0.87 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.27 | -0.57 | -0.87 | -0.87 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.20 | -0.57 | -0.84 | -0.85 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with IDIX
- Portfolio NameUser Type
- ProSeth Klarman - Baupost Group
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- ContributorMost-Active Stocks for the ...
- ContributorStocks Under-$10 Moving Hig...
- Userdonnieny7 Portfolio 1 Specu...
- ContributorStocks Rising On Unusual Vo...
- Usernew
- UserLong Term Stock Picks
- ContributorStocks Under-$10 Setting Up...
Latest IDIX Headlines from TheStreet
- Idenix Announces Data Presentation At The 48th Annual Meeting Of The European Association For The Study Of The Liver (EASL) 04.08.13 | 04:04 pm
- Idenix Loses First Phase Of Patent Dispute With Gilead Sciences 03.25.13 | 07:03 am
- Stock Futures Rise as Cyprus Deal Is Clinched 03.25.13 | 06:03 am
- Idenix Pharmaceuticals Announces Decision By The United States Patent And Trademark Office Patent Trial And Appeal Board In The First Phase Of The Interference 03.22.13 | 04:03 pm
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences 02.26.13 | 04:02 pm
- Idenix Pharmaceuticals Reports Fourth Quarter And Year Ended 2012 Financial Results 02.25.13 | 04:02 pm
- Fisking Ray Dirks on Medgenics and Shaming Seeking Alpha 02.11.13 | 09:02 pm
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences 02.05.13 | 04:02 pm
- Idenix Pharmaceuticals Provides Update On IDX184 And IDX19368 Development Programs 02.04.13 | 04:02 pm
Press Releases for IDIX
- Idenix Pharmaceuticals Announces Declaration Of A Patent Interference By The USPTO - PR Newswire 03.06.12 | 08:03 am
- Idenix Pharmaceuticals Elects Thomas Hodgson As Chairman Of The Board And Appoints Michael Wyzga To Its Board Of Directors - PR Newswire 03.01.12 | 04:03 pm
- Idenix Pharmaceuticals To Present At Three Upcoming Investor Conferences - PR Newswire 02.29.12 | 04:02 pm
- Idenix Pharmaceuticals To Present At The Citi Global Healthcare Conference - PR Newswire 02.21.12 | 04:02 pm
- Idenix To Host Conference Call Discussing Fourth Quarter And Year End 2011 Financial Results And Pipeline Update - PR Newswire 02.16.12 | 08:02 am
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.07.12 | 04:02 pm
- BioMed Realty Trust To Acquire Cambridge Place For $119 Million - PR Newswire 02.06.12 | 05:02 pm
- Idenix Announces Removal Of The Partial Clinical Hold On HCV Nucleotide Inhibitor, IDX184 - PR Newswire 02.03.12 | 08:02 am
- Idenix Reports Advancement Of HCV Development Pipeline - PR Newswire 01.09.12 | 07:01 am
- Idenix Reports Positive Interim Data For HCV Nucleotide Inhibitor, IDX184 - PR Newswire 01.09.12 | 07:01 am
Partner Headlines for IDIX
- DFC Global Lowers Outlook and 2 Other Stocks At 52-Week Lows - Wall St. Cheat Sheet 04.02.13 | 09:04 am
- Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling - Seeking Alpha 12.02.12 | 09:12 am
- RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November - Benzinga 12.01.12 | 01:12 pm
- New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 3 - Seeking Alpha 11.30.12 | 08:11 am
- UPDATE: Deutsche Bank Initiates Coverage on Idenix Pharmaceuticals with Buy Rating, $7 PT - Benzinga 11.28.12 | 09:11 am
- Morning Market Losers - Benzinga 09.19.12 | 09:09 am
- Idenix's Candidate on Clinical Hold - Analyst Blog - NASDAQ 08.30.12 | 10:08 pm
- Bad News for Bristol-Myers - Analyst Blog - NASDAQ 08.27.12 | 10:08 pm
- Bad News for Bristol-Myers - Analyst Blog - Zacks 08.27.12 | 06:08 pm
- UPDATE: Oppenheimer Maintains Idenix Pharmaceuticals at Perform Following Clinical Hold on IDX19368 - Benzinga 08.27.12 | 01:08 pm
